Glaukos reports Q2 adjusted EPS (52c), consensus (51c)

Reports Q2 revenue $95.7M, consensus $88.89M. “Our record second quarter results reflect successful global execution of our key strategic plans and growing momentum in our business,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”